Rewalk Robotics

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Rewalk Robotics

Berichtdoor Munnybunny » 07 Jul 2017 16:55

Break a leg or ready to run (again)..
Ik ga een gokje wagen.

Portland police officer, paralyzed from waist down, stands for promotion to sergeant

http://www.oregonlive.com/portland/inde ... aly_1.html

Paralyzed Navy SEAL veteran to receive ‘ReWalk’ robotic legs

https://sofrep.com/79664/paralyzed-navy ... otic-legs/



Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 11 Jul 2017 11:48

Zeer goed nieuws :D

ReWalk Robotics Announces French Distribution Agreement with Harmonie Médical Service
PRNewswire
July 11, 2017 5:00am

Exclusive Agreement with One of France's Largest Medical Device Providers To Facilitate Distribution of ReWalk Systems to the Spinal Cord Injured Community
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, July 11, 2017 /PRNewswire/ -- ReWalk Robotics Ltd.

("ReWalk" or the "Company"), a leading manufacturer of exoskeleton systems, announced today that the Company has signed a new, exclusive distribution agreement in France with Harmonie Médical Service (HMS). Through the agreement, HMS will serve as the sole distributor of ReWalk exoskeleton systems to qualifying candidates with spinal cord injury (SCI) across France. HMS, one of the largest medical device providers in the country, will be able to distribute both ReWalk Personal systems for use in the home and community and ReWalk Rehabilitation systems in clinical rehabilitation settings of providers working with individuals with SCI.

"The partnership with HMS provides an ideal structure to allow paralyzed individuals throughout France the ability to walk again," said Jodi Gricci, Chief Commercial Officer of ReWalk Robotics. "Starting in 2011, Dr. Jacques Kerdraon at Kerpape demonstrated leadership and built data to show the value of this technology. As the product is now available for everyday use at home and in the community, HMS provides the resources, support structure and quality as a leading provider of products for injured individuals."

"Our partnership with ReWalk is a real opportunity for HMS," said Sébastien Chamereau, Head of Disability Activity for Harmonie Médical Service. "We have been working for 30 years in the medical materials domain with people who have lost their mobility. We have always looked for innovative technologies in this domain, especially with the arrival of the first stand-up wheelchairs and, later, intelligent control systems. Our goal is to provide maximum autonomy to our customers in their everyday lives. The ReWalk 6.0 offers new medical and social opportunities to individuals with spinal cord injury. In signing this exclusive distribution contract with ReWalk, HMS will foster the arrival of this new technology throughout France. It is when I saw sparkles in the eyes and a large smile on the face of a young paraplegic man using a ReWalk system that I knew why I really wanted to provide this product in France."

Established in 1789, HMS is a renowned health service provider in France, with branches throughout the country and more than 500 employees. The distribution agreement with ReWalk will apply to all of the HMS offices across France.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 19 Jul 2017 08:47

Rewalk has been talking up its upcoming “soft exoskeleton” since January. The Boston-based company finally took the system out for a spin in the daylight, showing what it’s capable of at a robotics event held on the MIT campus this weekend. The version on display is still a prototype, but all of the functionality is in place, using a motorized pulley system to bring mobility to legs impacted by stroke.


http://thetechlicense.com/2017/07/18/re ... -patients/

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 22 Jul 2017 09:20

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, July 20, 2017 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq:RWLK), a leading manufacturer of exoskeleton systems, will release its second quarter 2017 financial results on Thursday, August 3, 2017, before the U.S. financial markets open.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 25 Jul 2017 13:22

Vlaamse exoskeletten moeten zwaar werk verlichten

Universiteiten en bedrijven onderzoeken economische relevantie van robotpakken

De twee universiteiten VUB en KUL willen samen met twintig bedrijven uit verschillende sectoren de handen in elkaar slaan om de economische relevantie van exoskeletten te onderzoeken. Zulke superpakken kunnen zware arbeid verlichten en het uitsterven van de constructie-arbeider voorkomen.

Terwijl de discussie over de definitie van zware beroepen nog hevig woedt, kijken bedrijven en wetenschappers al een stap verder. Exoskeletten zouden kunnen helpen om fysiek zware jobs een stuk te verlichten.

Bij verwarmingsspecialist Daikin zijn ze al een tijdje op zoek naar een manier om de fysieke arbeid van hun operatoren te verlichten. Ze weten bijvoorbeeld dat er al heel wat exoskeletten op de markt zijn. "Maar hoe kunnen wij nu weten welke oplossing het beste is voor onze werknemers?"

https://www.demorgen.be/dmselect/vlaams ... -bf2f0a5f/

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 28 Jul 2017 10:20

ReWalk Robotics leert opnieuw lopen

ReWalk Robotics is een innovatief bedrijf dat exoskeletten maakt en verkoopt aan personen met letsel aan de ruggengraat. In 2014 werd ReWalk Robotics het eerste robotica bedrijf dat FDA goedkeuring heeft gekregen voor exoskeletten voor persoonlijk gebruik. De missie is om de kwaliteit van het leven te verbeteren voor deze individuen die gebonden zijn aan hun rolstoel. Het bedrijf heeft hoofdkantoren in de VS, Israël en Duitsland.

ReWalk Robotics heeft het erg moeilijk gehad na haar beursgang. Het aandeel bereikte binnen enkele dagen na de beursgang een waarde van 44 dollar. Dit was in december 2014. Het aandeel viel in een vrijval na de beursgang tot net iets meer dan 5 dollar tegen het einde van 2016. Hierna steeds de koers plotseling naar ongeveer 17 dollar om vervolgens weer te zakken naar de huidige koers rond de 1 dollar.

OP DE BEURS BIEDEN RESULTATEN UIT HET VERLEDEN GEEN GARANTIE VOOR DE TOEKOMST

Dat het verleden er slecht uitzag, betekent echter niet dat de toekomst er hetzelfde uit zal zien. Wij denken namelijk dat dit aandeel weer zal herstellen. Wij zien namelijk dat het concept van exoskeletten nog niet helemaal is doorgedrongen tot de het grote publiek. De enorme potentie van deze industrie is niet te ontkennen en ReWalk positioneert zich momenteel erg goed in deze industrie.

Het bedrijf is nog steeds verlieslatend. Bij de afgelopen kwartaalcijfers een verlies van 6,4 miljoen in het eerste kwartaal van 2017, tegen een verlies van 6,9 miljoen in het eerste kwartaal van 2016. De omzet groeide wel nog steeds; er werd een omzet van 2,5 miljoen gerapporteerd in het eerste kwartaal van 2017, in vergelijking met de 2,1 miljoen in het eerste kwartaal van 2016 een stijging van ongeveer 21 procent jaar op jaar.

het bedrijf groeit een stuk minder hard dan een jaar geleden toen het een omzetgroei van 224 procent liet zien. Het spreekt echter voor zich dat een bedrijf niet op deze manier kan blijven groeien. Een langzamere groei, van alsnog 21 procent, gecombineerd met een kleiner verlies en veel nieuwe orders is in onze ogen positief.

Lees meer: Wie gebruiken robots nu al in het dagelijks leven?

GOED NIEUWS VOOR HET AANDEEL REWALK ROBOTICS

Iets meer dan een week geleden kwam er goed nieuws naar buiten voor het aandeel ReWalk Robotics. Omdat het bedrijf medische apparatuur produceert is de FDA een belangrijke factor in het succes van het bedrijf. De apparatuur is erg duur en bedrijf heeft de focus voornamelijk op de individu in en rond het huis. Over het algemeen kan een particulier dit niet betalen en dan komt de verzekeraar in het spel -die uiteraard niet wil betalen.

Het is dus van groot belang dat er bewezen wordt dat de exoskeletten daadwerkelijk toegevoegde waarde heeft voor de patiënt. Vorige week vond er een bewijskrachtige hoorzitting in Florida plaats die in het voordeel uitviel van ReWalk Robotics. Het kwam erop naar dat de rechtbank oordeelde, na het horen van verschillende experts, dat Blue Cross Blue Shield (een medische verzekeraar) exoskeletten moet vergoeden voor patienten met letsel aan hun ruggengraat. . Rewalk Ceo Larry Jasinski zei het volgende:

"The recent Florida ruling is significant and consistent with the growing body of established scientific data that supports the value of exoskeletal walking. We are encouraged by the chorus of experts who are supporting paralyzed individuals in their appeals processes, and heartened by the trend of coverage rulings that continues to increase in states across the U.S. It is our fervent hope that insurance companies will stop this arduous process of appeals and formulate standard operating policies for coverage of all eligible SCI plan members."

Hierop volgend kwam deze week het nieuws naar buiten dat ReWalk met een nieuw soort exoskellet komt, dat voornamelijk gericht is op patiënten die een beroerte hebben gehad.


“As we looked at exoskeletons from our experience with spinal cord injury, there were many things that apply for someone who may have had a stroke, but their needs are different,” said Jasinski. “This device helps someone who’s having trouble lifting their foot, trouble walking.” Aldus Jansinki.

Lees meer: Slim beleggen in intelligente robotica.

HET AANDEEL REWALK ROBOTICS MOET OPNIEUW LEREN LOPEN

Op het nieuws van het nieuwe exoskelet steeg het aandeel met ruim 40 procent. Voornamelijk omdat het toegankelijker is. Zo weegt het een stuk minder dan de 23 kilogram die de ReWalk 6.0 (het "normale" exoskelet) weegt. Daarnaast is het een minder robuust apparaat en zal het ook significant minder gaan kosten dan de 77.000 dollar van de Rewalk 6.0 -al is het nog niet bepaald hoeveel het wel zal gaan kosten.

Het lijkt erop dat ReWalk zich beter aan het positioneren is. Een nieuw product en uitkerende verzekeraars kunnen weleens de ommekeer zijn in de neerwaartse spiraal waarin het aandeel zich sinds haar beursgang in bevond. Een aandeel met potentie en een nobel doel. Interessant om in de gaten te houden.

https://beleggen.marktgevoel.nl/aandeel-rewalk-robotics

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 28 Jul 2017 11:08

Robotic suit promotes normal walking in stroke patients

Wyss technology opens new approaches to gait retraining and rehabilitation

July 27, 2017

“This study provides a glimpse of a new future where much of patient care will be carried out at home with the help of human-friendly robots, which look nothing like the robots we see in television and movies. This exosuit looks more like sports clothing than R2-D2, yet it is equally programmable and carries out tasks on command; however, the exosuit is lightweight, flexible, virtually invisible to others, and individualizes itself for each patient.

“We hope that it will soon enter clinical use where it undoubtedly could transform the lives of stroke patients for the better,” said Wyss Institute Director Donald Ingber.

http://news.harvard.edu/gazette/story/2 ... rmal-gait/

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 02 Aug 2017 14:44

Foundational Study Shows Soft Suit Exoskeleton Improves Walking for Stroke Survivors
Study Examines Use of Restore™ System Developed by Harvard's Wyss Institute


MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug. 2, 2017 /PRNewswire-USNewswire/ -- A new study published in the Journal of Science Translational Medicine finds that use of a soft suit exoskeleton system facilitates normal walking ability for ambulatory patients following a stroke. The paper, which is authored by researchers at Harvard University's Wyss Institute for Biologically Inspired Engineering and Boston University, is a seminal study, providing key findings that will propel additional research of how to improve mobility for patients following a stroke.

The prototype utilized in the study is a soft suit exoskeleton created by the Wyss Institute that is now moving towards commercialization by ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk"). The study included 9 participants, and examined the immediate improvements in walking capability that could be obtained when wearing the Restore system. The study highlighted the potential for the technology to provide gait assistance and training during walking and concludes:

These improvements in paretic limb function contributed to a 20 +/- 4% reduction in forward propulsion interlimb asymmetry and a 10 +/- 3% reduction in the energy cost of walking, which is equivalent to a 32+/- 9% reduction in the metabolic burden associated with poststroke walking. Relatively low assistance (~12% of biological torques) delivered with a lightweight and nonrestrictive exosuit was sufficient to facilitate more normal walking in ambulatory individuals after stroke.

"This foundational study shows that soft wearable robots can have significant positive impact on gait functions in patients post-stroke, and it is the result of a translational-focused multidisciplinary team of engineers, designers, biomechanists, physical therapists and most importantly patients who volunteered for this study and gave valuable feedback that guided our research," said Wyss Core Faculty member Conor Walsh who is also the John L. Loeb Associate Professor of Engineering and Applied Sciences at SEAS and the Founder of the Harvard Biodesign Lab.

ReWalk is working with the Wyss Institute on the development of lightweight designs to complete clinical studies, pursue regulatory approvals and commercialize the systems on a global scale. The first commercial application will be for stroke survivors, followed by Multiple Sclerosis patients and then additional applications. There are an estimated 3 million stroke survivors with lower limb disability in the U.S.

"Exoskeletons are now a commercially available, disruptive technology that have changed the lives of many individuals in the paraplegic community," said ReWalk CEO Larry Jasinski. "The ongoing research at the Wyss Institute on soft exosuits adds a new dimension to exoskeletons that can potentially meet the needs of individuals that have had a stroke, as well as for those diagnosed with Multiple Sclerosis, Parkinson's disease or people who have limitations in walking. The Restore is a unique lightweight design that can assist and constantly adjust in real time to the user's needs on every step they take. The depth of this fundamental science is a meaningful element in applying research to the everyday needs of this patient community."

The Restore transmits power to key joints of the legs with cable technologies, powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury. The cables are connected to fabric-based designs that attach to the legs and foot, thus lending the name "soft suit."

The full article in the Journal of Science Translational Medicine can be downloaded here.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 03 Aug 2017 14:39

Rewalk Robotics Reports Second Quarter 2017 Financial Results
Get notified next time RWLK.US makes a similar move!
The following excerpt is from the company's SEC filing.

-- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million

-- 11 favorable commercial case-by-case insurance coverage decisions --

-- 217 pending insurance claims in the U.S. and Germany --

-- Unveiled Restore soft-exosuit for stroke patients --

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 3, 2017

– ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “the Company”) today announced its financial results for the three- and six-month periods ended June 30, 2017.

Highlights of and subsequent to the second quarter include:

Total revenue for the second quarter of 2017 grew 146% year-over-year to $2 million, compared to $817,000 for the second quarter of 2016;

Placed 31 ReWalk units during the second quarter, of which 17 were placed in the U.S., 11 were in our direct markets in Europe, and three were in other markets

Increased pending insurance claims to 217 in the U.S. and Germany, as of the end of the quarter;

Secured 11 favorable commercial insurance coverage decisions;

Announced a Florida court ruling that Blue Cross Blue Shield of Florida must provide coverage of a ReWalk exoskeleton system for a plan member;

Signed exclusive distribution agreement in France with Harmonie Medical Service (HMS), one of the largest medical device providers in the country; and

Unveiled the Restore lightweight soft-exosuit base design for clinical studies and commercialization of an initial indication designed for stroke patients.

“This was another strong quarter for ReWalk as we advanced our key initiatives: securing insurance reimbursement coverage for the ReWalk personal device, expanding our global footprint and progressing our innovative ‘soft suit’ exoskeleton technology designed for individuals with stroke. We’ve submitted extensive data for review by a large commercial insurer in the U.S. and await a decision. We believe that a positive coverage decision would be an important catalyst for our business and the industry. It would also reflect the growing consensus among multiple courts and insurers who have determined, on a case by case basis, that our technology is not experimental and offers health benefits to its users,

stated Larry Jasinski, Chief Executive Officer.

“At the same time, we are excited to have introduced our Restore lightweight ‘soft suit’ design for stroke patients. We plan to begin clinical studies and pursue regulatory approvals so that we can commercialize the Restore in 2018, in order to broaden the reach of our technology to the millions of patients who can benefit from access to the device,” he added.

Second Quarter 2017 Financial Results

Total revenue was $2 million for the second quarter of 2017, an increase of 146% compared with $817,000 in the second quarter of 2016. 31 ReWalk units were placed during the second quarter, compared with 25 ReWalk systems placed in the prior year period, of which 17 were placed in the U.S., 11 in Europe, and three with distributors.

Gross margin improved to 37% during the second quarter of 2017 compared to 10% in the prior year period, primarily attributable to the increase in volume, conversion of rental units to purchases, and lower product costs.

Total operating expenses in the second quarter of 2017 were $6.1 million compared with $8.7 million in the second quarter of 2016.

Operating expenses in the second quarter of 2017 reflect initiatives to reduce spending announced earlier in 2017. Second quarter 2016 expenses include a one-time R&D charge related to the licensing agreement with the Wyss Institute at Harvard University.

Net loss was $6.3 million for the second quarter of 2017 compared with a net loss of $9.1 million in the prior year quarter. Non-GAAP net loss for the second quarter was $4.9 million compared with a non-GAAP net loss of $8.0 million in the second quarter of 2016.*

*A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.

Liquidity

As of June 30, 2017, ReWalk had $16.3 million in cash on its balance sheet.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 07 Aug 2017 13:32

Restore Exosuit Could Help MS Patients Improve Their Walking Ability, Study Reports

An exoskeleton developed by Harvard University researchers could restore multiple sclerosis patients’ balance and some of their walking capability, according to a study.

ReWalk Robotics is moving toward commercializing the system, developed at Harvard’s Wyss Institute for Biologically Inspired Engineering. In addition to MS patients, the exosuit should help people with Parkinson’s and other neurodegenerative conditions, researchers said.

https://multiplesclerosisnewstoday.com/ ... y-to-walk/